Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis.

Theranostics·2023

Same author

Emerging memristive artificial neuron and synapse devices for the neuromorphic electronics era.

Nanoscale horizons·2023

Same author

Cytotoxic tetronic acid derivatives from the mangrove endophytic fungus Hypomontagnella monticulosa YX702.

Fitoterapia·2023

Same author

Application and evaluation of surgical tool and tool tip recognition based on Convolutional Neural Network in multiple endoscopic surgical scenarios.

Surgical endoscopy·2023

Same author

Flexible BaTiO<sub>3</sub>-PDMS Capacitive Pressure Sensor of High Sensitivity with Gradient Micro-Structure by Laser Engraving and Molding.

Polymers·2023

Same author

miR-186-5p targets TGFβR2 to inhibit RAW264.7 cell migration and proliferation during mouse skin wound healing.

Environmental toxicology·2023

Same journal

Formulary Substitution of Proton Pump Inhibitors Based on Acquisition Price: Changes in Usage and Costs of Acid-Suppressant Therapies.

P & T : a peer-reviewed journal for formulary management·2021

Same journal

Is Ciprofloxacin in Combination With Beta-lactam Antibiotics a Recipe for Thrombocytosis?: A Case Report of Thrombocytosis in a Patient Receiving Ciprofloxacin and Ceftriaxone.

P & T : a peer-reviewed journal for formulary management·2021

Same journal

Looking for Trouble: Identifying and Treating Hypotension.

P & T : a peer-reviewed journal for formulary management·2019

Same journal

Research Briefs.

P & T : a peer-reviewed journal for formulary management·2019

Same journal

The Impact of Self-Monitoring Blood Glucose Adherence On Glycemic Goal Attainment in an Indigent Population, With Pharmacy Assistance.

P & T : a peer-reviewed journal for formulary management·2019

Same journal

Continuous Glucose Monitoring: A Review of Available Systems.

P & T : a peer-reviewed journal for formulary management·2019

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Warfarin pharmacogenomics.

Jiayi Li, Shan Wang, Joseph Barone

P & T : a Peer-Reviewed Journal for Formulary Management

|February 9, 2010

Summary

This summary is machine-generated.

Warfarin dosing is complex due to individual responses. Genetic variations in CYP 2C9 and VKORC1 influence warfarin metabolism and effectiveness, requiring dose adjustments for patient safety.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

Pharmacogenomics
Clinical Pharmacology

Background:

Warfarin is a critical anticoagulant for thromboembolic disease.
Challenges in warfarin therapy include narrow therapeutic index, bleeding risk, and patient variability.
Optimizing warfarin dosage is crucial for safe and effective treatment.

Purpose of the Study:

To investigate the impact of genetic variations on warfarin pharmacokinetics and pharmacodynamics.
To understand how CYP 2C9 and VKORC1 gene polymorphisms affect warfarin maintenance doses.

Main Methods:

Analysis of single-nucleotide polymorphisms (SNPs) in CYP 2C9 and VKORC1 genes.
Correlation of specific genetic alleles and haplotypes with warfarin dose requirements.

Main Results:

CYP 2C9*2 and CYP 2C9*3 alleles are associated with slower warfarin metabolism and lower maintenance doses.
The VKORC1 A haplotype is linked to reduced VKORC1 mRNA expression and lower warfarin maintenance doses.
Genetic factors significantly contribute to inter-individual variability in warfarin response.

Conclusions:

CYP 2C9 and VKORC1 genotypes are key determinants of warfarin dose.
Pharmacogenetic testing can aid in achieving safer and more effective warfarin therapy.
Personalized warfarin dosing strategies based on genetic profiles are warranted.